Molecular pathogenesis of bilateral breast cancer

Cancer Letters

Volumn 191, Issue 1, 2003, Pages 1-7

  Imyanitov, Evgeny N ^a   Hanson, Kaido P ^a  

^a N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

Author keywords

Bilateral breast cancer; BRCA genes; CHEK2; Clonality; CYP19; ERBB2; HER2; Mutations; Polymorphism; Risk factors

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ALLELE; BILATERAL CANCER; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER SUSCEPTIBILITY; DISEASE COURSE; EPIDEMIOLOGICAL DATA; GENE FUNCTION; GENETIC POLYMORPHISM; HUMAN; METASTASIS; MOLECULAR CLONING; MOLECULAR GENETICS; ONCOGENE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SHORT SURVEY; SOMATIC MUTATION;

EID: 0037470404     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(02)00523-2     Document Type: Review

References (53)

1. Leis H.P. Jr. Bilateral breast cancer. Surg. Clin. North. Am. 58:1978;833-841.
2. Donovan A.J. Bilateral breast cancer. Surg. Clin. North. Am. 70:1990;1141-1149.
3. Dawson L.A., Chow E., Goss P.E. Evolving perspectives in contralateral breast cancer. Eur. J. Cancer. 34:1998;2000-2009.
4. Chen Y., Thompson W., Semenciw R., Mao Y. Epidemiology of contralateral breast cancer. Cancer Epidemiol. Biomarkers Prev. 8:1999;855-861.
5. Chaudary M.A., Millis R.R., Hoskins E.O., Halder M., Bulbrook R.D., Cuzick J., Hayward J.L. Bilateral primary breast cancer: a prospective study of disease incidence. Br. J. Surg. 71:1984;711-714.
6. Robbins G.F., Berg J.W. Bilateral primary breast cancers; A prospective clinicopathological study. Cancer. 17:1964;1501-1527.
7. Leis H.P. Jr. Managing the remaining breast. Cancer. 46:1980;1026-1030.
8. McSweeney M.B., Egan R.L. Bilateral breast carcinoma. Recent Results Cancer Res. 90:1984;41-48.
9. Urban J.A., Papachristou D., Taylor J. Bilateral breast cancer: biopsy of the opposite breast. Cancer. 40:1977;1968-1973.
10. Ringberg A., Palmer B., Linell F., Rychterova V., Ljungberg O. Bilateral and multifocal breast carcinoma: a clinical and autopsy study with special emphasis on carcinoma in situ. Eur. J. Surg. Oncol. 17:1991;20-29.
11. Nielsen M., Thomsen J.L., Primdahl S., Dyreborg U., Andersen J.A. Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies. Br. J. Cancer. 56:1987;814-819.
12. Welch H.G., Black W.C. Using autopsy series to estimate the disease 'reservoir' for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann. Intern. Med. 127:1997;1023-1028.
13. Noguchi S., Motomura K., Inaji H., Imaoka S., Koyama H. Differentiation of primary and secondary breast cancer with clonal analysis. Surgery. 115:1994;458-462.
14. Shibata A., Tsai Y.C., Press M.F., Henderson B.E., Jones P.A., Ross R.K. Clonal analysis of bilateral breast cancer. Clin. Cancer Res. 2:1996;743-748.
15. Stenmark-Askmalm M., Gentile M., Wingren S., Stahl O. Protein accumulation and gene mutation of p53 in bilateral breast cancer. South-East Sweden Breast Cancer Group, Acta Oncol. 40:2001;56-62.
16. Janschek E., Kandioler-Eckersberger D., Ludwig C., Kappel S., Wolf B., Taucher S., Rudas M., Gnant M., Jakesz R. Contralateral breast cancer: molecular differentiation between metastasis and second primary cancer. Breast Cancer Res. Treat. 67:2001;1-8.
17. Imyanitov E.N., Suspitsin E.N., Grigoriev M.Y., Togo A.V., Kuligina S.E., Belogubova E.V., Pozharisski K.M., Turkevich E.A., Rodriquez C., Cornelisse C.J., Hanson K.P., Theillet C. Concordance of allelic imbalance profiles in synchronous and metachronous bilateral breast carcinomas. Int. J. Cancer. 100:2002;557-564.
18. Dawson P.J., Maloney T., Gimotty P., Juneau P., Ownby H., Wolman S.R. Bilateral breast cancer: one disease or two? Breast Cancer Res. Treat. 19:1991;233-244.
19. Holmberg L., Adami H.O., Ekbom A., Bergstrom R., Sandstrom A., Lindgren A. Prognosis in bilateral breast cancer, effects of time interval between first and second primary tumours. Br. J. Cancer. 58:1988;191-194.
20. Healey E.A., Cook E.F., Orav E.J., Schnitt S.J., Connolly J.L., Harris J.R. Contralateral breast cancer: clinical characteristics and impact on prognosis. J. Clin. Oncol. 11:1993;1545-1552.
21. Heron D.E., Komarnicky L.T., Hyslop T., Schwartz G.F., Mansfield C.M. Bilateral breast carcinoma: risk factors and outcomes for patients with synchronous and metachronous disease. Cancer. 88:2000;2739-2750.
22. Newman L.A., Sahin A.A., Cunningham J.E., Bondy M.L., Mirza N.Q., Vlastos G.S., Whitman G.J., Brown H., Buchholz T.A., Lee M.H., Singletary S.E., case-control A. study of unilateral and bilateral breast carcinoma patients. Cancer. 91:2001;1845-1853.
23. Knudson A.G. Jr. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. USA. 68:1971;820-823.
24. Greene M.H. Genetics of breast cancer. Mayo Clin. Proc. 72:1997;54-65.
25. Nicoletto M.O., Donach M., De Nicolo A., Artioli G., Banna G., Monfardini S. BRCA-1 and BRCA-2 mutations as prognostic factors in clinical practice and genetic counselling. Cancer Treat. Rev. 27:2001;295-304.
26. Eccles D.M., Englefield P., Soulby M.A., Campbell I.G. BRCA1 mutations in southern England. Br. J. Cancer. 77:1998;2199-2203.
27. Papelard H., de Bock G.H., van Eijk R., Vliet-Vlieland T.P., Cornelisse C.J., Devilee P., Tollenaar R.A. Prevalence of BRCA1 in a hospital-based population of Dutch breast cancer patients. Br. J. Cancer. 83:2000;719-724.
28. Steinmann D., Bremer M., Rades D., Skawran B., Siebrands C., Karstens J.H., Dork T. Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer. Br. J. Cancer. 85:2001;850-858.
29. Kollias J., Man S., Marafie M., Carpenter K., Pinder S., Ellis I.O., Blamey R.W., Cross G., Brook J.D. Loss of heterozygosity in bilateral breast cancer. Breast Cancer Res. Treat. 64:2000;241-251.
30. Bergthorsson J.T., Ejlertsen B., Olsen J.H., Borg A., Nielsen K.V., Barkardottir R.B., Klausen S., Mouridsen H.T., Winther K., Fenger K., Niebuhr A., Harboe T.L., Niebuhr E. BRCA1 and BRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age. J. Med. Genet. 38:2001;361-368.
31. Loman N., Johannsson O., Kristoffersson U., Olsson H., Borg A. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. J. Natl. Cancer Inst. 93:2001;1215-1223.
32. Lidereau R., Soussi T. Absence of p53 germ-line mutations in bilateral breast cancer patients. Hum. Genet. 89:1992;250-252.
33. Fukutomi T., Inoue R., Ushijima T., Tsuda H., Adachi I. Bilateral breast cancer in a patient with a strong family history of cancer: analysis of p53 germ line mutations. Breast Cancer. 1:1994;151-155.
34. Shafman T.D., Levitz S., Nixon A.J., Gibans L.A., Nichols K.E., Bell D.W., Ishioka C., Isselbacher K.J., Gelman R., Garber J., Harris J.R., Haber D.A. Prevalence of germline truncating mutations in ATM in women with a second breast cancer after radiation therapy for a contralateral tumor. Genes Chromosomes Cancer. 27:2000;124-129.
35. Broeks A., Urbanus J.H., Floore A.N., Dahler E.C., Klijn J.G., Rutgers E.J., Devilee P., Russell N.S., van Leeuwen F.E., van't Veer L.J. ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. Am. J. Hum. Genet. 66:2000;494-500.
36. Ingvarsson S. Molecular genetics of breast cancer progression. Semin. Cancer Biol. 9:1999;277-288.
37. Kinoshita T., Ueda M., Enomoto K., Ikeda T., Kikuchi K., Ishii S., Kitajima M. Comparison of p53 gene abnormalities in bilateral and unilateral breast cancer. Cancer. 76:1995;2504-2509.
38. Ackerman J., Baunoch D.A., Gimotty P., George J., Lane M.A., Dawson P.J. The role of p53 mutations in bilateral breast carcinoma. Mod. Pathol. 8:1995;244-248.
39. Ozer E., Canda T., Kuyucuodlu F. p53 mutations in bilateral breast carcinoma: correlation with Ki-67 expression and the mean nuclear volume. Cancer Lett. 122:1998;101-106.
40. Matsuo K., Fukutomi T., Tsuda H., Akashi-Tanaka S., Shimizu C., Hasegawa T. Differences in estrogen receptor status; HER2, and p53 comparing metachronous bilateral breast carcinoma. J. Surg. Oncol. 77:2001;31-34.
41. Matsuo K., Fukutomi T., Akashi-Tanaka S., Hasegawa T., Tsuda H. Histological grade, p53, HER2 and hormone receptor status of synchronous bilateral breast carcinoma. Breast Cancer. 9:2002;127-133.
42. Safal M., Lower E.E., Hasselgren P.O., Hungness E.S., Gazder P., Aron B., Shaughnessy E.A., Yassin R. Bilateral synchronous breast cancer and HER-2/neu overexpression. Breast Cancer Res. Treat. 72:2002;195-201.
43. Imyanitov E.N., Togo A.V., Suspitsin E.N., Grigoriev M.Y., Pozharisski K.M., Turkevich E.A., Hanson K.P., Hayward N.K., Chenevix-Trench G., Theillet C., Lavin M.F. Evidence for microsatellite instability in bilateral breast carcinomas. Cancer Lett. 154:2000;9-17.
44. Kiang D.T., Kennedy B.J., Snover D.C. Biological and histological characteristics of simultaneous bilateral breast cancer. Lancet. 2:1980;1105-1107.
45. Coradini D., Oriana S., Mariani L., Miceli R., Bresciani G., Marubini E., Di Fronzo G. Is steroid receptor profile in contralateral breast cancer a marker of independence of the corresponding primary tumour? Eur. J. Cancer. 34:1998;825-830.
46. Hemminki K., Granstrom C. Morphological types of breast cancer in family members and multiple primary tumours: is morphology genetically determined? Breast Cancer Res. 4:2002;R7.
47. Wistuba I.I., Tomlinson G.E., Behrens C., Virmani A., Geradts J., Blum J.L., Minna J.D., Gazdar A.F. Two identical triplet sisters carrying a germline BRCA1 gene mutation acquire very similar breast cancer somatic mutations at multiple other sites throughout the genome. Genes Chromosomes Cancer. 28:2000;359-369.
48. Delgado L., Fernandez G., Gonzalez A., Bressac-de Paillerets B., Gualco G., Bombled J., Cataldi S., Sabini G., Roca R., Muse I.M. Hereditary breast cancer associated with a germline BRCA2 mutation in identical female twins with similar disease expression. Cancer Genet. Cytogenet. 133:2002;24-28.
49. Dunning A.M., Healey C.S., Pharoah P.D., Teare M.D., Ponder B.A., Easton D.F., systematic A. review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 8:1999;843-854.
50. Vahteristo P., Bartkova J., Eerola H., Syrjakoski K., Ojala S., Kilpivaara O., Tamminen A., Kononen J., Aittomaki K., Heikkila P., Holli K., Blomqvist C., Bartek J., Kallioniemi O.P., Nevanlinna H. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am. J. Hum. Genet. 71:2002;432-438.
51. Suspitsin E.N., Grigoriev M.Y., Togo A.V., Kuligina E.S., Belogubova E.V., Pozharisski K.M., Chagunava O.L., Sokolov E.P., Theillet C., Berstein L.M., Hanson K.P., Imyanitov E.N. Distinct prevalence of the type CYP19 delta3 (TTTA)7 allele in premenopausal versus postmenopausal breast cancer patients, but not in control individuals. Eur. J. Cancer. 38:2002;1911-1916.
52. Kuligina E.S., Togo A.V., Suspitsin E.N., Grigoriev M.Y., Pozharisskiy K.M., Chagunava O.L., Berstein L.M., Theillet C., Hanson K.P., Imyanitov E.N. CYP17 polymorphism in the groups of distinct breast cancer susceptibility: comparison of patients with the bilateral disease vs. monolateral breast cancer patients vs. middle-aged female controls vs. elderly tumor-free women. Cancer Lett. 156:2000;45-50.
53. E.N. Suspitsin, K.G. Buslov, M.Yu Grigoriev, J.G. Ishutkina, J.M. Ulibina, V.M. Gorodinskaya, K.M. Pozharisski, L.M. Berstein, K.P. Hanson, A.V. Togo, E.N. Imyanitov, Evidence against involvement of p53 polymorphism in breast cancer predisposition. Int. J. Cancer, submitted.